PDS Biotechnology/PDSB

$5.54

2.21%
-
1D1W1MYTD1YMAX

About PDS Biotechnology

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted immunotherapies for cancer and infectious diseases based on its Versamune, Versamune plus PDS0301, and Infectimune T cell-activating platforms. Its lead clinical candidate, PDS0101, is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a range of HPV16-associated cancers. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment. PDS0102, PDS0103, PDS0104, PDS0201, PDS0202, and PDS0203 are also in its pipeline of Versamune and Infectimune-based therapies.

Ticker

PDSB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Frank Bedu-Addo

Employees

26

Headquarters

Princeton, United States

PDSB Metrics

BasicAdvanced
$168.6M
Market cap
-
P/E ratio
-$1.70
EPS
1.67
Beta
-
Dividend rate

What the Analysts think about PDSB

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
218.95% upside
High $21.00
Low $14.00
$5.54
Current price
$17.67
Average price target

PDSB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-10.8M
-6.09%
Profit margin
0%
-

PDSB Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.47%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.67
-$0.32
-$0.37
-$0.35
-
Expected
-$0.29
-$0.31
-$0.35
-$0.45
-$0.44
Surprise
133.33%
4.67%
6.58%
-21.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell PDS Biotechnology stock

Buy or sell PDS Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing